Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares are rising 19% in Friday’s trading session, after the drug maker announced that it has entered into a definitive …
The biotech world is experiencing volatility in the midst of a drug development discontinuation for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) and word from the FDA to …
Thursday turned out to be a nightmare for shareholders of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), after the company announced disappointing interim data from its two …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the second quarter ended June …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced that it has initiated a significant reduction in its workforce in order to focus the company’s financial resources in …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced that preclinical data on the combination of evofosfamide with immune checkpoint inhibitors will be presented in a scientific poster …
In a research report released this morning, Cantor analyst Daniel Brims reiterated a Buy rating on shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), with a …
In a research report released today, Edison analyst Philippa Gardner offered a commentary on Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), as the company’s earlier-stage hypoxia asset, Tarloxitinib (TH-4000), has now …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or “tarloxotinib” (TH-4000), for the …
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) received another set of praises from analysts at Cantor in a research note released yesterday.
